Session 3 - An update to the nmCRPC treatment landscape: optimising treatment outcomes and quality of life (QoL)
In Session 3, learn about the following topics:
-
Update on nmCRPC and European Association of Urology (EAU) Guidelines - Professor Philip Cornford
-
Defining and providing holistic patient care - Louisa Fleure
-
Presentation of a nmCRPC clinical case and discussion - Professor Amit Bahl and panel
This promotional meeting series has been initiated and funded by Bayer and is for GB healthcare professionals only.
NUBEQA▼ (darolutamide) Prescribing Information can be found here.
Xofigo▼ (radium223 dichloride) Prescribing Information can be found here.
Speakers
Professor Philip Cornford - FRCS (Urol), MD, PGCT&L
Honorary Associate Professor
Liverpool University Hospitals NHS Foundation Trust
Chair of EAU Prostate Cancer Guidelines Panel
Professor Amit Bahl - MD, FRCP, FRCR
Consultant Clinical Oncologist
Bristol Cancer Institute
University Hospitals Bristol and Weston NHS Foundation Trust
Louisa Fleure - MSc
Consultant Nurse
Guy’s and St Thomas’ NHS Foundation Trust
Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email: pvuk@bayer.com.
If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.
